share_log

Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know

Benzinga ·  May 15 23:01

In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings30100
Last 30D10000
1M Ago00000
2M Ago10000
3M Ago10100

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $3.75, a high estimate of $5.00, and a low estimate of $2.00. Marking an increase of 25.0%, the current average surpasses the previous average price target of $3.00.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment